SEARCH:   Advanced

Blood, Vol. 111, Issue 9, 4477-4489, May 1, 2008 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Blood Möricke et al. 111: 4477 Supplemental materials for: Moricke et al Files in this Data Supplement: Document 1. ALL-BFM 95 committee members and participating centers and clinicians (PDF, 23.1 KB) Table S1. Clinical features in trials ALL-BFM 90 and 95 (PDF, 47.9 KB) Table S2. Cox regression analysis of prognostic factors (PDF, 16.4 KB) Table S3. Clinical characteristics in the randomization groups Protocol M and MCA (assigned arms) (PDF, 16.2 KB) Table S4. Toxicity in the randomization groups Protocol M and MCA (assigned arms) (PDF, 11.2 KB) - Selected parameters according to National Cancer Institute common toxicity criteria (NCI-CTC) This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020